Swedbank’s Arcutis Biotherapeutics ARQT Stock Holding History

Swedbank’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-36,600	Closed	-$699K	–	719
2022 Q3	$699K	Buy	+36,600	New	+$829K	﹤0.01%	663

Other funds holding ARQT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Swedbank's ARQT Position: Q4 2022 in Review

Swedbank sold out of Arcutis Biotherapeutics (ARQT) in Q4 2022, closing a stake of 36,600 shares — an estimated $699K sold.

Swedbank first reported a position in ARQT in Q3 2022 and held it in 1 quarter. The position peaked at $699K in Q3 2022. 141 funds tracked by Wall St. Rank hold ARQT as of Q4 2022.

Swedbank reported no remaining Arcutis Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Swedbank sold 36,600 Arcutis Biotherapeutics shares in Q4 2022, an estimated $699K.
Swedbank first reported a position in Arcutis Biotherapeutics in Q3 2022 and held it in 1 quarter.
Swedbank's Arcutis Biotherapeutics position peaked at $699K in Q3 2022.
141 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2022.

Based on Swedbank's 13F filing for Q4 2022, filed 6 Dec 2024.